Research at Dana-Farber Cancer Institute Inc. has led to the identification of new interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
Researchers from Oregon Health and Science University (OHSU) are seeking patent protection for a transcervical delivery device that may provide clinicians with a simple, inexpensive office-based procedure for the assessment of tubal patency or delivery of a permanent contraceptive agent to the fallopian tube.
Chongqing Fuan Pharmaceutical (Group) Co. Ltd. has prepared and tested class of 7-((5-membered heterocyclic)methyl)-8-carboxylic acid-benzo cyclic borate derivatives reported to be useful for the treatment of bacterial infections.
Chengdu Easton Biopharmaceuticals Co. Ltd. has identified cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.
Cgenetech (Suzhou, China) Co. Ltd. has synthesized tyrosine-protein kinase JAK2 inhibitors reported to be useful for the treatment of autoimmune diseases, myeloproliferative diseases and graft-versus-host disease.
Pharward Biotechnology Inc. Pte Ltd. has disclosed compounds acting as E3 ubiquitin-protein ligase SIAH1 modulators reported to be useful for the treatment of cocaine dependence.
In what represents its first patenting, Copenhagen, Denmark-based HEI Therapeutics ApS reported seeking patent protection for a point-of-care or home monitoring solution, which enables personalized treatment for hypothyroidism.
Inventors affiliated with Nirsense LLC, are designing somatic and cerebral oximetry devices using functional near-infrared spectroscopy (fNIRS). They have filed for patent protection of wearable systems capable of detecting both optical and non-optical biometric properties of a user to determine their cognitive state.
Institute of Cancer Research UK has described lysyl oxidase homolog 2 (LOXL2) inhibitors reported to be useful for the treatment of cancer and fibrosis.